Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration
Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the fo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ghigo, E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Anmerkung: |
© Italian Society of Endocrinology (SIE) 1994 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of endocrinological investigation - [S. l.] : Springer, 1978, 17(1994), 3 vom: März, Seite 157-162 |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:1994 ; number:3 ; month:03 ; pages:157-162 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03347707 |
|---|
| Katalog-ID: |
SPR036812498 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036812498 | ||
| 003 | DE-627 | ||
| 005 | 20230519181924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1994 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03347707 |2 doi | |
| 035 | |a (DE-627)SPR036812498 | ||
| 035 | |a (SPR)BF03347707-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghigo, E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| 264 | 1 | |c 1994 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Italian Society of Endocrinology (SIE) 1994 | ||
| 520 | |a Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. | ||
| 700 | 1 | |a Arvat, E. |4 aut | |
| 700 | 1 | |a Rizzi, G. |4 aut | |
| 700 | 1 | |a Bellone, J. |4 aut | |
| 700 | 1 | |a Nicolosi, M. |4 aut | |
| 700 | 1 | |a Boffano, G. M. |4 aut | |
| 700 | 1 | |a Mucci, M. |4 aut | |
| 700 | 1 | |a Boghen, M. F. |4 aut | |
| 700 | 1 | |a Camanni, F. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of endocrinological investigation |d [S. l.] : Springer, 1978 |g 17(1994), 3 vom: März, Seite 157-162 |w (DE-627)369556267 |w (DE-600)2119482-8 |x 1720-8386 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:1994 |g number:3 |g month:03 |g pages:157-162 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03347707 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 1994 |e 3 |c 03 |h 157-162 | ||
| author_variant |
e g eg e a ea g r gr j b jb m n mn g m b gm gmb m m mm m f b mf mfb f c fc |
|---|---|
| matchkey_str |
article:17208386:1994----::riienacshgothroeeesnatvtoayteihxppiehpiedryuntno |
| hierarchy_sort_str |
1994 |
| publishDate |
1994 |
| allfields |
10.1007/BF03347707 doi (DE-627)SPR036812498 (SPR)BF03347707-e DE-627 ger DE-627 rakwb eng Ghigo, E. verfasserin aut Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Italian Society of Endocrinology (SIE) 1994 Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. Arvat, E. aut Rizzi, G. aut Bellone, J. aut Nicolosi, M. aut Boffano, G. M. aut Mucci, M. aut Boghen, M. F. aut Camanni, F. aut Enthalten in Journal of endocrinological investigation [S. l.] : Springer, 1978 17(1994), 3 vom: März, Seite 157-162 (DE-627)369556267 (DE-600)2119482-8 1720-8386 nnns volume:17 year:1994 number:3 month:03 pages:157-162 https://dx.doi.org/10.1007/BF03347707 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 17 1994 3 03 157-162 |
| spelling |
10.1007/BF03347707 doi (DE-627)SPR036812498 (SPR)BF03347707-e DE-627 ger DE-627 rakwb eng Ghigo, E. verfasserin aut Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Italian Society of Endocrinology (SIE) 1994 Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. Arvat, E. aut Rizzi, G. aut Bellone, J. aut Nicolosi, M. aut Boffano, G. M. aut Mucci, M. aut Boghen, M. F. aut Camanni, F. aut Enthalten in Journal of endocrinological investigation [S. l.] : Springer, 1978 17(1994), 3 vom: März, Seite 157-162 (DE-627)369556267 (DE-600)2119482-8 1720-8386 nnns volume:17 year:1994 number:3 month:03 pages:157-162 https://dx.doi.org/10.1007/BF03347707 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 17 1994 3 03 157-162 |
| allfields_unstemmed |
10.1007/BF03347707 doi (DE-627)SPR036812498 (SPR)BF03347707-e DE-627 ger DE-627 rakwb eng Ghigo, E. verfasserin aut Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Italian Society of Endocrinology (SIE) 1994 Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. Arvat, E. aut Rizzi, G. aut Bellone, J. aut Nicolosi, M. aut Boffano, G. M. aut Mucci, M. aut Boghen, M. F. aut Camanni, F. aut Enthalten in Journal of endocrinological investigation [S. l.] : Springer, 1978 17(1994), 3 vom: März, Seite 157-162 (DE-627)369556267 (DE-600)2119482-8 1720-8386 nnns volume:17 year:1994 number:3 month:03 pages:157-162 https://dx.doi.org/10.1007/BF03347707 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 17 1994 3 03 157-162 |
| allfieldsGer |
10.1007/BF03347707 doi (DE-627)SPR036812498 (SPR)BF03347707-e DE-627 ger DE-627 rakwb eng Ghigo, E. verfasserin aut Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Italian Society of Endocrinology (SIE) 1994 Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. Arvat, E. aut Rizzi, G. aut Bellone, J. aut Nicolosi, M. aut Boffano, G. M. aut Mucci, M. aut Boghen, M. F. aut Camanni, F. aut Enthalten in Journal of endocrinological investigation [S. l.] : Springer, 1978 17(1994), 3 vom: März, Seite 157-162 (DE-627)369556267 (DE-600)2119482-8 1720-8386 nnns volume:17 year:1994 number:3 month:03 pages:157-162 https://dx.doi.org/10.1007/BF03347707 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 17 1994 3 03 157-162 |
| allfieldsSound |
10.1007/BF03347707 doi (DE-627)SPR036812498 (SPR)BF03347707-e DE-627 ger DE-627 rakwb eng Ghigo, E. verfasserin aut Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Italian Society of Endocrinology (SIE) 1994 Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. Arvat, E. aut Rizzi, G. aut Bellone, J. aut Nicolosi, M. aut Boffano, G. M. aut Mucci, M. aut Boghen, M. F. aut Camanni, F. aut Enthalten in Journal of endocrinological investigation [S. l.] : Springer, 1978 17(1994), 3 vom: März, Seite 157-162 (DE-627)369556267 (DE-600)2119482-8 1720-8386 nnns volume:17 year:1994 number:3 month:03 pages:157-162 https://dx.doi.org/10.1007/BF03347707 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 17 1994 3 03 157-162 |
| language |
English |
| source |
Enthalten in Journal of endocrinological investigation 17(1994), 3 vom: März, Seite 157-162 volume:17 year:1994 number:3 month:03 pages:157-162 |
| sourceStr |
Enthalten in Journal of endocrinological investigation 17(1994), 3 vom: März, Seite 157-162 volume:17 year:1994 number:3 month:03 pages:157-162 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of endocrinological investigation |
| authorswithroles_txt_mv |
Ghigo, E. @@aut@@ Arvat, E. @@aut@@ Rizzi, G. @@aut@@ Bellone, J. @@aut@@ Nicolosi, M. @@aut@@ Boffano, G. M. @@aut@@ Mucci, M. @@aut@@ Boghen, M. F. @@aut@@ Camanni, F. @@aut@@ |
| publishDateDaySort_date |
1994-03-01T00:00:00Z |
| hierarchy_top_id |
369556267 |
| id |
SPR036812498 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036812498</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519181924.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03347707</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036812498</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03347707-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ghigo, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Italian Society of Endocrinology (SIE) 1994</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arvat, E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rizzi, G.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bellone, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nicolosi, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boffano, G. M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mucci, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boghen, M. F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Camanni, F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of endocrinological investigation</subfield><subfield code="d">[S. l.] : Springer, 1978</subfield><subfield code="g">17(1994), 3 vom: März, Seite 157-162</subfield><subfield code="w">(DE-627)369556267</subfield><subfield code="w">(DE-600)2119482-8</subfield><subfield code="x">1720-8386</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:3</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:157-162</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03347707</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">1994</subfield><subfield code="e">3</subfield><subfield code="c">03</subfield><subfield code="h">157-162</subfield></datafield></record></collection>
|
| author |
Ghigo, E. |
| spellingShingle |
Ghigo, E. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| authorStr |
Ghigo, E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)369556267 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1720-8386 |
| topic_title |
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of endocrinological investigation |
| hierarchy_parent_id |
369556267 |
| hierarchy_top_title |
Journal of endocrinological investigation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)369556267 (DE-600)2119482-8 |
| title |
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| ctrlnum |
(DE-627)SPR036812498 (SPR)BF03347707-e |
| title_full |
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| author_sort |
Ghigo, E. |
| journal |
Journal of endocrinological investigation |
| journalStr |
Journal of endocrinological investigation |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
txt |
| container_start_page |
157 |
| author_browse |
Ghigo, E. Arvat, E. Rizzi, G. Bellone, J. Nicolosi, M. Boffano, G. M. Mucci, M. Boghen, M. F. Camanni, F. |
| container_volume |
17 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ghigo, E. |
| doi_str_mv |
10.1007/BF03347707 |
| title_sort |
arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (ghrp-6) in elderly but not in young subjects after oral administration |
| title_auth |
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| abstract |
Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. © Italian Society of Endocrinology (SIE) 1994 |
| abstractGer |
Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. © Italian Society of Endocrinology (SIE) 1994 |
| abstract_unstemmed |
Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging. © Italian Society of Endocrinology (SIE) 1994 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
3 |
| title_short |
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration |
| url |
https://dx.doi.org/10.1007/BF03347707 |
| remote_bool |
true |
| author2 |
Arvat, E. Rizzi, G. Bellone, J. Nicolosi, M. Boffano, G. M. Mucci, M. Boghen, M. F. Camanni, F. |
| author2Str |
Arvat, E. Rizzi, G. Bellone, J. Nicolosi, M. Boffano, G. M. Mucci, M. Boghen, M. F. Camanni, F. |
| ppnlink |
369556267 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03347707 |
| up_date |
2024-07-03T19:43:00.345Z |
| _version_ |
1803588238413135872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036812498</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519181924.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03347707</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036812498</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03347707-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ghigo, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Italian Society of Endocrinology (SIE) 1994</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 µg/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24–32 yr) and 8 elderly (age 66–85 yr) subjects were studied. In all the GH response to GHRH (1 µg/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean±SE, IGF-I: 65.1±9.1 vs 142.9±9.4 µg/L, p<0.0001; GH peak: 5.4±1.0 vs 13.6 ± 0.8 µg/L, p<0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9±2.0 vs 16.2±5.4 µg/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1±3.3 µg/L, p<0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5±3.4 µg/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p<0.05). In conclusion, present results show that in humans oral GHRP-6 administration induces a clear GH increase also in aging. The finding that ARG enhanced the activity of GHRP-6 in elderly but not in young subjects suggests that ARG is able to enhance the somatotropic responsiveness to GHRP-6 only when somatostatinergic activity is increased, i.e. in aging. Treatment with oral GHRP-6 alone or combined with low oral ARG may be hypothesized to restore GH secretion in aging.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arvat, E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rizzi, G.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bellone, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nicolosi, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boffano, G. M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mucci, M.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boghen, M. F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Camanni, F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of endocrinological investigation</subfield><subfield code="d">[S. l.] : Springer, 1978</subfield><subfield code="g">17(1994), 3 vom: März, Seite 157-162</subfield><subfield code="w">(DE-627)369556267</subfield><subfield code="w">(DE-600)2119482-8</subfield><subfield code="x">1720-8386</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:3</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:157-162</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03347707</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">1994</subfield><subfield code="e">3</subfield><subfield code="c">03</subfield><subfield code="h">157-162</subfield></datafield></record></collection>
|
| score |
7.400567 |